Micheline LeBlanc knew something was up in the summer of 2022. She felt achy and fatigued. “Headaches were a big problem. Night sweats were dramatic,” LeBlanc says.

When she developed throbbing pain in her legs and shortness of breath, her husband took her to the hospital, where she was diagnosed with Lyme disease.

They sent her home with antibiotics. But a few days later her doctor called to tell her a blood test showed she actually had a different tick-borne illness – babesiosis.

The first case of babesiosis in the U.S. was identified on Nantucket Island in 1969. The tick-borne parasitic disease is endemic in New England, and as deer ticks expand their range it’s now found from Virginia to Maine as well as the upper Midwest, from Michigan to Minnesota. The CDC points to a significant increase in incidence over the last decade.

Babesiosis can be treated with drugs, typically a seven to 10 days course of an antibiotic, azithromycin combined with atovaquone, which are both prescription medications. But, sometimes, this isn’t enough to kill off the parasite, and there’s a risk of relapse.

Now, researchers are launching a randomized, controlled clinical trial, slated to begin this month, to test whether the anti-malaria drug — tafenoquine — in combination with the other drugs already used, can speed up recovery and clear the parasite from patients’ bodies faster.

Most younger people who get infected after a tick bite have only mild illness. “A fever that can take a couple of days to a week or two to go away,” says Linden Hu, an infectious disease doctor at Tufts University. Some people have no symptoms. But some people over 50 as well as those with compromised immune systems can become very ill and end up in the hospital.

That’s what happened to LeBlanc, “It was a roller coaster ride,” she says.

LeBlanc lives in New Hampshire, where ticks are common. She would feel better for a few weeks, but then her symptoms would return. She had headaches and fatigue. LeBlanc had her spleen removed in her 20s after an infection and her immune system was compromised from a prior illness which put her at high risk.

“These patients can have many relapses, lasting months or sometimes even years,” explains Dr. Peter Krause, an infectious disease physician and babesiosis expert at the Yale School of Public health. And a small percentage die.

A small case study published last month provides some initial evidence that tafenoquine is beneficial for these patients. The study included five people including LeBlanc, 72.

When doctors added tafenoquine to these patients' regimen, they got better.

“It worked,” Dr. Krause says. “They no longer had symptoms and they no longer had the organism in their blood.”

When LeBlanc went to the hospital for testing after taking the drug, the doctors began to document a significant decline in the parasite within a few weeks. “It went down and down, and then it was not even found in my system,” she says. And she started to feel much better, “I was elated,” LeBlanc says.

Now she's back doing all the things she couldn’t do while she was sick, such as dancing and volunteering. “It’s just great,” LeBlanc says.

Researchers plan to enroll hospitalized patients this summer who are admitted with babesiosis, explains Edouard Vannier of Tufts Medical Center, one of the trial sites. “Now the tick season has started we are going to see patients coming to the hospital,” Vannier says.

He says they will not include patients with mild disease because the existing drug regimen of azithromycin combined with atovaquone already does a good job. He says enrollment should be “up and running very shortly.”

Currently tafenoquine is approved by the FDA for malaria treatment and prevention. For now, doctors are using the drug ‘off-label’ in babesiosis patients, but the ongoing research could pave the way for FDA expanded approval of the drug for the tick-borne disease. “That’s our goal,” says Dr. Geoff Dow, CEO of 60 Degrees Pharma.

Given the rise of babesiosis, there’s also more testing for the disease. It can be diagnosed with a blood test. The FDA recommends blood donation screening for the parasite that causes babesiosis in 15 states.

LeBlanc says she’s now very careful now to avoid tick bites. The CDC advises people to protect themselvesby walking on trails, using repellent, wearing long-sleeve pants and shirts when outdoors, especially in wooded areas and showering soon after being outdoors. And be especially careful in spring, summer and fall when ticks are most active.

Find Allison Aubrey on Instagram at @allison.aubrey and on X @AubreyNPR.

This story was edited by Jane Greenhalgh

Copyright 2024 NPR

Transcript

ROB SCHMITZ, HOST:

Nasty tick-borne illness is on the rise throughout the Northeast, and it's spreading into the Midwest. It was once called Nantucket fever because the first cases were documented on that Massachusetts island more than 50 years ago. But now, a sign of hope - this month, a new clinical trial begins to test a medicine aimed at treating the infection. NPR's Allison Aubrey reports.

ALLISON AUBREY, BYLINE: Micheline LeBlanc knew something was up in the summer of 2022. She felt fatigued, lost her appetite, and had body aches.

MICHELINE LEBLANC: Headaches were a big problem. Night sweats were dramatic.

AUBREY: When she developed throbbing pain in her legs and shortness of breath, her husband took her to the hospital.

LEBLANC: The ER staff ran scans and tests. And when I left the ER, I had been diagnosed with Lyme disease.

AUBREY: They sent her home with antibiotics. But later that week, her doctor called to tell her that a blood test showed she actually had a different tick-borne illness, babesiosis, which she said she'd never heard of.

LEBLANC: I didn't even know what to say. I just thought, oh, and she said, well, it's a tick disease.

AUBREY: LeBlanc lives in New Hampshire, where tick-borne illnesses have become more prevalent, including babesiosis. Here's doctor Linden Hu of Tufts University.

LINDEN HU: It does seem to be following the trend of Lyme disease and entering into areas where Lyme disease is prevalent.

AUBREY: Babesiosis is caused by a parasite that infects red blood cells and spreads primarily through deer ticks. Dr. Hu has treated patients with it.

HU: For most people, babesiosis - it's pretty mild, and it's just a fever that can take a couple days to a week or two to go away.

AUBREY: Micheline LeBlanc's doctors gave her two medicines and she did get better, but within a month or so, her symptoms came back.

LEBLANC: It was a roller coaster ride. I would get better, but I always felt like I was relapsing.

AUBREY: LeBlanc is 72 years old and had her spleen removed in her 20s. She knew she had a weakened immune system. And Dr. Peter Krause of Yale University says this put her in a high-risk category.

PETER KRAUSE: These patients usually have many relapses lasting months or sometimes even years, and there's about a 20% mortality rate.

AUBREY: Dr. Krause and his collaborators had found that an anti-malaria drug called tafenoquine could help clear the parasite in animal studies, and some doctors had begun to use the drug off-label to treat patients with relapsing babesiosis. Dr. Krause assessed a small group of patients, including LeBlanc, who took tafenoquine along with two other drugs, and he says it worked.

KRAUSE: They no longer had symptoms, and they no longer had the organism in their blood.

AUBREY: The clinical trial that starts this month will test whether adding tafenoquine to existing treatments will help clear the disease faster among people who are hospitalized. LeBlanc says once they added tafenoquine to her regimen, she got much better. For months, blood test had shown the parasite was still there.

LEBLANC: Finally, it was tafenoquine, and started to go down, and went down, and then it was, you know, not even found in my system. I was elated.

AUBREY: It's been about a year, and she says her life feels normal again. She's back to line dancing and volunteering and doing all the things she enjoys.

Allison Aubrey, NPR News. Transcript provided by NPR, Copyright NPR.

300x250 Ad

Support quality journalism, like the story above, with your gift right now.

Donate